Byondis
Jan Schouten is a distinguished professional in the field of molecular biology and cell line engineering, currently serving as the Chairman of the Works Council and Principal Scientist at Byondis since April 2020, where the focus includes exploring AI/ML applications in pharmaceuticals. Prior experiences include a decade at Synthon Biopharmaceuticals BV, where Jan held roles as Principal Scientist and Senior Project Leader, specializing in molecular biology, cell line development, and antibody discovery. Jan's career also includes significant positions at Crucell, LUMC, Clusius Laboratory, and TNO, contributing to advancements in recombinant protein production and gene expression regulation. Jan earned a PhD in Molecular Biology from Leiden University.
This person is not in any teams
This person is not in any offices
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.